No Benefit With Intensified Postinduction in Pediatric Standard-Risk Acute Lymphoblastic Leukemia
For the entire cohort of pediatric patients with standard-risk acute lymphoblastic leukemia, overall survival at 6 years was greater than 95%.
For the entire cohort of pediatric patients with standard-risk acute lymphoblastic leukemia, overall survival at 6 years was greater than 95%.
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
Induction therapy with blinatumomab did not appear to confer a survival benefit, though undergoing stem cell transplant did.
The TEAMM trial sought to assess time to first febrile episode or death from all causes in patients with newly diagnosed myeloma who received antibiotic prophylaxis vs those who did not.
Researchers determined the 5-year overall and disease-free survival for patients with CSCC of the head and neck who received adjuvant radiation therapy.
Mental health disorders may be an adverse effect of head and neck cancer diagnosis, treatment, or treatment morbidities.
Disparities between NCCN guideline-concordant treatment and actual care were most likely to occur in two patient populations.
Patients referred to the clinic were diagnosed nearly 2 weeks faster compared with historical controls.
In patients with complete response at transplant, age was found to be the only predictor of clinical outcomes.
Exercise tolerance was found to be associated with verbal fluency, dominant motor speed, and math academics, among other neurocognitive metrics.